Invictus RG lessened its stake in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 80.2% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,874 shares of the medical instruments supplier’s stock after selling 19,796 shares during the quarter. Invictus RG’s holdings in OraSure Technologies were worth $110,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. State Street Corp boosted its holdings in shares of OraSure Technologies by 6.9% during the 2nd quarter. State Street Corp now owns 1,639,620 shares of the medical instruments supplier’s stock valued at $28,305,000 after acquiring an additional 106,326 shares during the last quarter. Federated Investors Inc. PA boosted its holdings in shares of OraSure Technologies by 505.6% in the second quarter. Federated Investors Inc. PA now owns 312,595 shares of the medical instruments supplier’s stock worth $5,395,000 after buying an additional 260,977 shares during the last quarter. USA Financial Portformulas Corp boosted its holdings in shares of OraSure Technologies by 31.0% in the second quarter. USA Financial Portformulas Corp now owns 56,653 shares of the medical instruments supplier’s stock worth $978,000 after buying an additional 13,421 shares during the last quarter. Chicago Equity Partners LLC boosted its holdings in shares of OraSure Technologies by 38.3% in the second quarter. Chicago Equity Partners LLC now owns 78,430 shares of the medical instruments supplier’s stock worth $1,354,000 after buying an additional 21,730 shares during the last quarter. Finally, 361 Capital LLC boosted its holdings in shares of OraSure Technologies by 59.9% in the second quarter. 361 Capital LLC now owns 26,974 shares of the medical instruments supplier’s stock worth $466,000 after buying an additional 10,107 shares during the last quarter. 94.48% of the stock is currently owned by hedge funds and other institutional investors.

In other OraSure Technologies news, CEO Douglas A. Michels sold 22,923 shares of the firm’s stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $23.00, for a total transaction of $527,229.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Mara G. Aspinall bought 5,000 shares of the firm’s stock in a transaction on Tuesday, November 7th. The shares were purchased at an average price of $14.23 per share, for a total transaction of $71,150.00. Following the purchase, the director now owns 5,000 shares in the company, valued at approximately $71,150. The disclosure for this purchase can be found here. 6.40% of the stock is currently owned by company insiders.

A number of research firms recently issued reports on OSUR. ValuEngine downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a report on Thursday, November 2nd. Zacks Investment Research raised shares of OraSure Technologies from a “hold” rating to a “buy” rating and set a $25.00 price objective on the stock in a report on Wednesday, September 20th. Jefferies Group downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a report on Thursday, November 2nd. Finally, Canaccord Genuity reissued a “buy” rating and issued a $22.00 price objective on shares of OraSure Technologies in a report on Tuesday, September 19th. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $18.21.

OraSure Technologies, Inc. (OSUR) opened at $17.37 on Friday. The stock has a market cap of $1,040.00, a P/E ratio of 32.44, a P/E/G ratio of 3.24 and a beta of 1.28. OraSure Technologies, Inc. has a 1-year low of $8.39 and a 1-year high of $23.01.

OraSure Technologies (NASDAQ:OSUR) last released its earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.09 EPS for the quarter, hitting analysts’ consensus estimates of $0.09. OraSure Technologies had a net margin of 20.48% and a return on equity of 14.12%. The company had revenue of $42.30 million for the quarter, compared to analysts’ expectations of $40.87 million. During the same quarter last year, the business earned $0.11 EPS. The firm’s revenue was up 31.0% compared to the same quarter last year. analysts anticipate that OraSure Technologies, Inc. will post 0.42 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/orasure-technologies-inc-osur-stake-lessened-by-invictus-rg/1753237.html.

OraSure Technologies Company Profile

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Institutional Ownership by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.